AKT1 and hepatocellular carcinoma: Other studies have demonstrated that the phosphoinositide-3-kinase (PI3K)/AKT pathway is critical for induction of resistance to sorafenib and impairment of AKT activity contributes to increased sensitivity to sorafenib of HCC cells [9].